Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data

Evangelos K Oikonomou, Mohamed Marwan, Milind Y Desai, Jennifer Mancio, Alaa Alashi, Erika Hutt Centeno, Sheena Thomas, Laura Herdman, Christos P Kotanidis, Katharine E Thomas, Brian P Griffin, Scott D Flamm, Alexios S Antonopoulos, Cheerag Shirodaria, Nikant Sabharwal, John Deanfield, Stefan Neubauer, Jemma C Hopewell, Keith M Channon, Stephan Achenbach, Charalambos Antoniades, Evangelos K Oikonomou, Mohamed Marwan, Milind Y Desai, Jennifer Mancio, Alaa Alashi, Erika Hutt Centeno, Sheena Thomas, Laura Herdman, Christos P Kotanidis, Katharine E Thomas, Brian P Griffin, Scott D Flamm, Alexios S Antonopoulos, Cheerag Shirodaria, Nikant Sabharwal, John Deanfield, Stefan Neubauer, Jemma C Hopewell, Keith M Channon, Stephan Achenbach, Charalambos Antoniades

Abstract

Background: Coronary artery inflammation inhibits adipogenesis in adjacent perivascular fat. A novel imaging biomarker-the perivascular fat attenuation index (FAI)-captures coronary inflammation by mapping spatial changes of perivascular fat attenuation on coronary computed tomography angiography (CTA). However, the ability of the perivascular FAI to predict clinical outcomes is unknown.

Methods: In the Cardiovascular RISk Prediction using Computed Tomography (CRISP-CT) study, we did a post-hoc analysis of outcome data gathered prospectively from two independent cohorts of consecutive patients undergoing coronary CTA in Erlangen, Germany (derivation cohort) and Cleveland, OH, USA (validation cohort). Perivascular fat attenuation mapping was done around the three major coronary arteries-the proximal right coronary artery, the left anterior descending artery, and the left circumflex artery. We assessed the prognostic value of perivascular fat attenuation mapping for all-cause and cardiac mortality in Cox regression models, adjusted for age, sex, cardiovascular risk factors, tube voltage, modified Duke coronary artery disease index, and number of coronary CTA-derived high-risk plaque features.

Findings: Between 2005 and 2009, 1872 participants in the derivation cohort underwent coronary CTA (median age 62 years [range 17-89]). Between 2008 and 2016, 2040 patients in the validation cohort had coronary CTA (median age 53 years [range 19-87]). Median follow-up was 72 months (range 51-109) in the derivation cohort and 54 months (range 4-105) in the validation cohort. In both cohorts, high perivascular FAI values around the proximal right coronary artery and left anterior descending artery (but not around the left circumflex artery) were predictive of all-cause and cardiac mortality and correlated strongly with each other. Therefore, the perivascular FAI measured around the right coronary artery was used as a representative biomarker of global coronary inflammation (for prediction of cardiac mortality, hazard ratio [HR] 2·15, 95% CI 1·33-3·48; p=0·0017 in the derivation cohort, and 2·06, 1·50-2·83; p<0·0001 in the validation cohort). The optimum cutoff for the perivascular FAI, above which there is a steep increase in cardiac mortality, was ascertained as -70·1 Hounsfield units (HU) or higher in the derivation cohort (HR 9·04, 95% CI 3·35-24·40; p<0·0001 for cardiac mortality; 2·55, 1·65-3·92; p<0·0001 for all-cause mortality). This cutoff was confirmed in the validation cohort (HR 5·62, 95% CI 2·90-10·88; p<0·0001 for cardiac mortality; 3·69, 2·26-6·02; p<0·0001 for all-cause mortality). Perivascular FAI improved risk discrimination in both cohorts, leading to significant reclassification for all-cause and cardiac mortality.

Interpretation: The perivascular FAI enhances cardiac risk prediction and restratification over and above current state-of-the-art assessment in coronary CTA by providing a quantitative measure of coronary inflammation. High perivascular FAI values (cutoff ≥-70·1 HU) are an indicator of increased cardiac mortality and, therefore, could guide early targeted primary prevention and intensive secondary prevention in patients.

Funding: British Heart Foundation, and the National Institute of Health Research Oxford Biomedical Research Centre.

Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Perivascular FAI analysis around epicardial coronary vessels (A) Perivascular FAI phenotyping of the proximal segments of all three major epicardial coronary vessels, with corresponding FAI colour maps. (B) Example of perivascular FAI phenotyping around the proximal RCA. Perivascular fat was defined as fat within a radial distance equal to the diameter (d) of the vessel. FAI=fat attenuation index. HU=Hounsfield unit. LAD=left anterior descending artery. LCx=left circumflex artery. RCA=right coronary artery.
Figure 2
Figure 2
Kaplan-Meier curves of all-cause mortality and cardiac mortality with high versus low perivascular FAI High values for the perivascular FAI were ≥–70·1 HU and low perivascular FAI values were

Figure 3

Incremental prognostic value of the…

Figure 3

Incremental prognostic value of the perivascular FAI beyond current coronary CTA-based risk stratification…

Figure 3
Incremental prognostic value of the perivascular FAI beyond current coronary CTA-based risk stratification Comparison of time-dependent ROC curves (at 6 years) and respective AUC of two nested models for discrimination of cardiac mortality in the (A) derivation and (B) validation cohorts. Model 1 represents the current state-of-the-art in risk assessment and consisted of age, sex, risk factors (hypertension, hypercholesterolaemia, diabetes mellitus, smoker status, epicardial adipose tissue volume), modified Duke coronary artery disease index, and number of high-risk plaque features on coronary CTA. Model 2 incorporates perivascular FAI values (≥–70·1 HU vs <–70·1 HU) into model 1. AUC=area under the curve. CTA=computed tomography angiography. FAI=fat attenuation index. HU=Hounsfield unit. ROC=receiver operating characteristic.

Figure 4

Subgroup analysis of the prognostic…

Figure 4

Subgroup analysis of the prognostic value of the perivascular FAI in patients with…

Figure 4
Subgroup analysis of the prognostic value of the perivascular FAI in patients with and without coronary artery disease Plots show adjusted HRs for high versus low perivascular FAI values (≥–70·1 HU vs <–70·1 HU) as a prognostic biomarker for (A) all-cause mortality and (B) cardiac mortality in different patient subgroups, with or without cardiac CTA-derived features of coronary artery disease. HRs are adjusted for age, sex, and epicardial adipose tissue volume. CTA=computed tomography angiography. FAI=fat attenuation index. HU=Hounsfield unit. HR=hazard ratio.
Figure 3
Figure 3
Incremental prognostic value of the perivascular FAI beyond current coronary CTA-based risk stratification Comparison of time-dependent ROC curves (at 6 years) and respective AUC of two nested models for discrimination of cardiac mortality in the (A) derivation and (B) validation cohorts. Model 1 represents the current state-of-the-art in risk assessment and consisted of age, sex, risk factors (hypertension, hypercholesterolaemia, diabetes mellitus, smoker status, epicardial adipose tissue volume), modified Duke coronary artery disease index, and number of high-risk plaque features on coronary CTA. Model 2 incorporates perivascular FAI values (≥–70·1 HU vs <–70·1 HU) into model 1. AUC=area under the curve. CTA=computed tomography angiography. FAI=fat attenuation index. HU=Hounsfield unit. ROC=receiver operating characteristic.
Figure 4
Figure 4
Subgroup analysis of the prognostic value of the perivascular FAI in patients with and without coronary artery disease Plots show adjusted HRs for high versus low perivascular FAI values (≥–70·1 HU vs <–70·1 HU) as a prognostic biomarker for (A) all-cause mortality and (B) cardiac mortality in different patient subgroups, with or without cardiac CTA-derived features of coronary artery disease. HRs are adjusted for age, sex, and epicardial adipose tissue volume. CTA=computed tomography angiography. FAI=fat attenuation index. HU=Hounsfield unit. HR=hazard ratio.

References

    1. Douglas PS, Hoffmann U, Patel MR. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372:1291–1300.
    1. SCOT-HEART investigators CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. Lancet. 2015;385:2383–2391.
    1. The National Institute for Health and Care Excellence (NICE) Chest pain of recent onset: assessment and diagnosis. November, 2016.
    1. Fishbein MC, Siegel RJ. How big are coronary atherosclerotic plaques that rupture? Circulation. 1996;94:2662–2666.
    1. Fleg JL, Stone GW, Fayad ZA. Detection of high-risk atherosclerotic plaque: report of the NHLBI working group on current status and future directions. JACC Cardiovasc Imaging. 2012;5:941–955.
    1. Matter CM, Stuber M, Nahrendorf M. Imaging of the unstable plaque: how far have we got? Eur Heart J. 2009;30:2566–2574.
    1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126.
    1. Antonopoulos AS, Sanna F, Sabharwal N. Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med. 2017;9:eaal2658.
    1. Taylor AJ, Cerqueira M, Hodgson JM. ACCF/SCCT/ACR/AHA/ASE/ASNC/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. J Cardiovasc Comput Tomogr. 2010;4:407–413.
    1. Greenland P, Alpert JS, Beller GA. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2010;122:2748–2764.
    1. Goff DC, Jr, Lloyd-Jones DM, Bennett G. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2935–2959.
    1. Budoff MJ, Achenbach S, Blumenthal RS. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation. 2006;114:1761–1791.
    1. Cury RC, Abbara S, Achenbach S. CAD-RADS(TM) Coronary Artery Disease–Reporting and Data System: an expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Radiology (ACR) and the North American Society for Cardiovascular Imaging (NASCI)—endorsed by the American College of Cardiology. J Cardiovasc Comput Tomogr. 2016;10:269–281.
    1. Min JK, Shaw LJ, Devereux RB. Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol. 2007;50:1161–1170.
    1. Puchner SB, Liu T, Mayrhofer T. High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial. J Am Coll Cardiol. 2014;64:684–692.
    1. Pencina MJ, D'Agostino RB, Pencina KM, Janssens AC, Greenland P. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol. 2012;176:473–481.
    1. Stone NJ, Robinson JG, Lichtenstein AH. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–2934.
    1. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210–215.
    1. Alexopoulos N, Melek BH, Arepalli CD. Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning) J Am Coll Cardiol. 2013;61:1956–1961.
    1. Mulvihill NT, Foley JB. Inflammation in acute coronary syndromes. Heart. 2002;87:201–204.
    1. Tarkin JM, Dweck MR, Evans NR. Imaging atherosclerosis. Circ Res. 2016;118:750–769.
    1. Camici PG, Rimoldi OE, Gaemperli O, Libby P. Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur Heart J. 2012;33:1309–1317.
    1. Fitzgerald K, White S, Borodovsky A. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41–51.
    1. Ridker PM, Everett BM, Thuren T. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.
    1. Sabatine MS, Giugliano RP, Keech AC. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
    1. Weintraub WS, Harrison DG. C-reactive protein, inflammation and atherosclerosis: do we really understand it yet? Eur Heart J. 2000;21:958–960.
    1. Joshi NV, Vesey AT, Williams MC. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383:705–713.
    1. Knaapen P, de Haan S, Hoekstra OS. Cardiac PET-CT: advanced hybrid imaging for the detection of coronary artery disease. Neth Heart J. 2010;18:90–98.
    1. Marwan M, Hell M, Schuhback A. CT attenuation of pericoronary adipose tissue in normal versus atherosclerotic coronary segments as defined by intravascular ultrasound. J Comput Assist Tomogr. 2017;41:762–767.
    1. Mahabadi AA, Balcer B, Dykun I. Cardiac computed tomography-derived epicardial fat volume and attenuation independently distinguish patients with and without myocardial infarction. PLoS One. 2017;12:e0183514.
    1. Hedgire S, Baliyan V, Zucker EJ. Perivascular epicardial fat stranding at coronary CT angiography: a marker of acute plaque rupture and spontaneous coronary artery dissection. Radiology. 2018;287:808–815.
    1. Dreisbach JG, Nicol ED, Roobottom CA, Padley S, Roditi G. Challenges in delivering computed tomography coronary angiography as the first-line test for stable chest pain. Heart. 2018;104:921–927.
    1. Sun Z, Choo GH, Ng KH. Coronary CT angiography: current status and continuing challenges. Br J Radiol. 2012;85:495–510.
    1. Otero HJ, Steigner ML, Rybicki FJ. The “post-64” era of coronary CT angiography: understanding new technology from physical principles. Radiol Clin North Am. 2009;47:79–90.
    1. Hong MK, Mintz GS, Lee CW. The site of plaque rupture in native coronary arteries: a three-vessel intravascular ultrasound analysis. J Am Coll Cardiol. 2005;46:261–265.

Source: PubMed

3
Subscribe